BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

GVK Bio announces new CEO for Aragen Bioscience

08 May 2019 | News

Dr. Schleyer has over two decades of industry experience



GVK BIO is pleased to announce the appointment of Dr. Axel Schleyer as Chief Executive Officer, Aragen Bioscience Inc. Aragen, a wholly-owned subsidiary of GVK BIO, is a leading Contract Research Organization focused on accelerating biologicals product development with an integrated offering that includes antibody discovery and humanization, stable cell line development, recombinant protein production and purification, and differentiated diseases models.

A seasoned Pharmaceutical and Biotechnology professional, Dr. Schleyer has over two decades of industry experience, building and leading high-performance teams, spearheading global business initiatives, and formulating business strategies resulting in successful outcomes. Prior to joining Aragen, Dr. Schleyer served as Senior Vice President, AGC Biologics and has held roles of increasing responsibilities at Lonza, Siegfried, Baxter Healthcare and Boehringer Ingelheim.

Dr. Schleyer has completed his postdoctoral studies at The Scripps Research Institute, La Jolla, CA and at Carlsberg Institute, Copenhagen, Denmark. He completed his Ph.D. in Chemistry from the University of Hamburg, and holds a Master of Business Administration degree from California State University, San Marcos.